Symptom changes with subcutaneous Foslevodopa/Foscarbidopa in adults with advanced Parkinson's disease in Belgium

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational collection of real-world outcomes in roughly 120 adults with advanced Parkinson's disease who are prescribed subcutaneous Foslevodopa/Foscarbidopa by their physicians. Participants receive the infusion as part of routine clinical care at about 15 hospital sites across Belgium and are followed for up to 18 months. Data will be collected during regular clinic visits with no extra procedures beyond standard care. The goal is to document symptom trajectories and treatment use in typical practice settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant diagnosed with Advanced Parkinson's Disease (PD), aged 18 years or older able to provide voluntary informed consent.
* Participant evaluated for commercially available continuous subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) in the hospital at the clinician's discretion as part of his/her routine clinical care and the intention to administer subcutaneous LDp/CDp made prior to and independent of recruitment into the study.

Exclusion Criteria:

* Participant participating in an interventional research study (not including noninterventional studies) during the administration of LDp/CDp.
* Participant evaluated for commercially available continuous subcutaneous LD/CDp outside of the hospital.

Where it's running

• Imelda Ziekenhuis /ID# 279436
  Bonheiden, Antwerpen, Belgium Recruiting
• Universitair Ziekenhuis Antwerpen /ID# 279434
  Edegem, Antwerpen, Belgium Recruiting
• Chu Tivoli /ID# 279455
  La Louvière, Hainaut, Belgium Recruiting
• Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 279452
  Tournai, Hainaut, Belgium Recruiting
• Jessa Ziekenhuis - Campus Virga Jesse /ID# 279454
  Hasselt, Limburg, Belgium Recruiting
• AZ Sint-Lucas /ID# 279453
  Ghent, Oost-Vlaanderen, Belgium Recruiting

Study contacts

• Study coordinator: Clementine Semanaz
• Email: clementine.semanaz@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder

  This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07882108

• Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment

  This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07868614

• Mental imagery with self-regulation to help daily activities in Parkinson's disease

  This study tests whether a six-week program of mental imagery combined with self-regulation can help people with Parkinson’s perform daily activities better than standard learning or exercise.

  Recruiting The Hong Kong Polytechnic University · Hong Kong · NCT07860294

• Real-world experiences of Inbrija for Parkinson's OFF episodes

  This study looks at how people with Parkinson’s who use Inbrija for OFF episodes feel and function in daily life.

  Recruiting Merz Pharmaceuticals GmbH · Altmünster and 1 other locations · NCT07797790

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Test of RO7568282 in early Parkinson's disease

  This study tests whether RO7568282, compared with placebo, is safe and helps people with early Parkinson's disease who are already taking levodopa.

  Recruiting at 4 sites Phase 2 Hoffmann-La Roche · Boca Raton, Florida and 3 other locations · NCT07781644

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.